Selection of appropriate endpoints for rare disease clinical studies can be challenging but is critical to assessing the efficacy of new medicines. Engaging with patient communities to determine endpoints ensures appropriate measurements of success for all stakeholders and de-risks recruitment and retention strategies. Post-approval, appropriately set clinical research endpoints result in meaningful treatment assessment and delivery by clinicians and patients.
In this white paper, you’ll learn:
- How to determine valid clinical research endpoints
- How to engage with patient advocacy organizations to support product development
- How to select endpoints relevant to all stakeholders including patients, caregivers, and practitioners
Explore related content and topics
Newsletter
RARE DISEASES NEWSLETTER Volume 13, May 2019
Welcome to the thirteenth edition of the rare diseases newsletter. This quarterly publication strives to keep you up to date on PRA's Center for Rare…
Resource
Rapid Participation Burden Survey
Quick, flexible, validated patient survey tool for rapid feedback on trial-specific participation burden, helps sponsors refine risk analyses and…
Publication
Three Necessary Steps When Designing your New World Protocol
This article explores the design of a protocol that includes decentralized components. After a clinical-trial protocol has been developed, adding…